The UK medical charity LifeArc has extended a research collaboration with Metrion Biosciences Ltd with the goal of identifying new compounds for neurological diseases using Metrion’s ion channel drug discovery technology. The year-old collaboration is being extended for a further 12 months.
“The success to date of this novel small molecule programme with Metrion is very motivating, especially as this lies in one of our three priority therapy areas,” said Justin Bryans, executive director for drug discovery at LifeArc. The therapy areas were not disclosed.